(Q37118188)

English

A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting

scientific article published on April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting (English)

1 reference

Europe PubMed Central

18 August 2017

0 references

1 reference

based on heuristic

inferred from title

5

object named as

W Martin Kast

1 reference

Europe PubMed Central

18 August 2017

author name string

Andrew Gray

1

1 reference

Europe PubMed Central

18 August 2017

Adam B Raff

2

1 reference

Europe PubMed Central

18 August 2017

Maurizio Chiriva-Internati

3

1 reference

Europe PubMed Central

18 August 2017

Si-Yi Chen

4

1 reference

Europe PubMed Central

18 August 2017

publication date

1 April 2008

1 reference

Europe PubMed Central

18 August 2017

Immunological Reviews

1 reference

Europe PubMed Central

18 August 2017

222

1 reference

Europe PubMed Central

18 August 2017

316-327

1 reference

Europe PubMed Central

18 August 2017

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Therapeutic dendritic cell vaccination of patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Immune resistance orchestrated by the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Immunosuppressive networks in the tumour environment and their therapeutic relevance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

CD8+ T-cell memory in tumor immunology and immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Tumors hamper the immunogenic competence of CD4+ T cell-directed dendritic cell vaccination

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Tregs and rethinking cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Premalignant lesions as targets for cancer vaccines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Immune responses in the draining lymph nodes against cancer: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Tumor escape mechanisms in prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Combinations of anticancer drugs and immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Prophylactic cancer vaccines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Thymic output in aged mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Therapeutic vaccination for HPV induced cervical cancers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Mechanisms used by human papillomaviruses to escape the host immune response.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Cancer vaccines: moving beyond current paradigms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Contribution of oncoproteomics to cancer biomarker discovery

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00605.X

21 January 2018

Identifiers

10.1111/J.1600-065X.2008.00605.X

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37118188&oldid=2139651265"